Products for Research Use Only
RegisterLogin

BML-280

CAT: 0804-HY-114095-02Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114095-02Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
BML-280 (VU0285655-1) is a potent and selective phospholipase D2 (PLD2) inhibitor. BML-280 has the ability to prevent caspase-3 cleavage and reduction in cell viability induced by high glucose. BML-280 can be used for rheumatoid arthritis research[1][2].
CAS Number
1158347-73-9
Product Name Alternative
VU0285655-1
UNSPSC
12352005
Target
Interleukin Related; Phospholipase; TNF Receptor
Type
Reference compound
Related Pathways
Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bml-280.html
Purity
99.64
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
O=C(C1=CC2=CC=CC=C2N=C1)NCCN(CC3)CCC3(N(C4=CC=CC=C4)CN5)C5=O
Molecular Formula
C25H27N5O2
Molecular Weight
429.51
References & Citations
[1]Burkhardt U, et al. Role of phospholipases D1 and 2 in astroglial proliferation: effects of specific inhibitors and genetic deletion. Eur J Pharmacol. 2015 Aug 15;761:398-404. |[2]Tenconi PE, et al. High glucose-induced phospholipase D activity in retinal pigment epithelium cells: New insights into the molecular mechanisms of diabetic retinopathy. Exp Eye Res. 2019 Jul;184:243-257.|[3]Tsai YR, et al. Inhibition of formyl peptide-stimulated phospholipase D activation by Fal-002-2 via blockade of the Arf6, RhoA and protein kinase C signaling pathways in rat neutrophils. Naunyn Schmiedebergs Arch Pharmacol. 2013 Jun;386 (6) :507-19.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-1; IL-8; PLD; TNFRSF5/CD40

Chemical Information

N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)quinoline-3-carboxamide
CAS Number1158347-73-9
PubChem CID44138050
IUPAC NameN-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl]quinoline-3-carboxamide
Molecular FormulaC25H27N5O2
Molecular Weight429.5
XLogP2.9
Topological Polar Surface Area77.6
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count5
Heavy Atom Count32
Formal Charge0
Complexity671
SMILES
C1CN(CCC12C(=O)NCN2C3=CC=CC=C3)CCNC(=O)C4=CC5=CC=CC=C5N=C4
InChI
InChI=1S/C25H27N5O2/c31-23(20-16-19-6-4-5-9-22(19)27-17-20)26-12-15-29-13-10-25(11-14-29)24(32)28-18-30(25)21-7-2-1-3-8-21/h1-9,16-17H,10-15,18H2,(H,26,31)(H,28,32)
InChIKey
WJOCDBUFEUKYNI-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)quinoline-3-carboxamide
CAS: 1158347-73-9
CID: 44138050
Formula: C25H27N5O2
MW: 429.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight429.5
XLogP32.9
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count5
Exact Mass429.21647512
Monoisotopic Mass429.21647512
Topological Polar Surface Area77.6 Ų
Heavy Atom Count32
Formal Charge0
Complexity671
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Related Products

CatalogName
HY-114023BML-288
HY-19987-01BML-284
HY-133095-01BML-260
HY-13946-01BML-277
HY-108348-01BML-259
HY-W025074-01BML-278
HY-113721BML-244
HY-100450-01BML-111
HY-15420-01BML-190
HY-19350-01BML-210

Alternative Products

CatalogName
BA3562-10BML-280
MBS131442BML-210, (BML210; BML 210)
MBS131522BML-284 (BML 284; BML284)
B1236-50BML-277
BA3821-25BML-259
BA4522-10BML-278
B1425-50BML-190
TRC-B595890-100MGBML-287
T200419-01BML-286
T89165-01BML-260

Popular Products